Evidence map›Paper›PMID 31660984›Full record

ArticleJournal of neuroinflammation2019

The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders.

Patrick Miller-Rhodes, Cuicui Kong, Gurpreet S Baht, Priyanka Saminathan, Ramona M Rodriguiz, William C Wetsel, Harris A Gelbard, Niccolò Terrando

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. A Neutrophil Membrane-Encapsulated Pd/hCeOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Animal models of delirium: a narrative review.Translational psychiatry · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Infectious Diseases.Advances in neurobiology · 2024
    Review
  10. Article
  11. Review
  12. A Review of the Biological Mechanisms of Dexmedetomidine for Postoperative Neurocognitive Disorders.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Review
  13. Review
  14. Article
  15. URMC-099 prophylaxis prevents hippocampal vascular vulnerability and synaptic damage in an orthopedic model of delirium superimposed on dementia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Patrick Miller-RhodesCenter for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Cuicui KongCenter for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA.
Gurpreet S BahtDepartment of Orthopedic Surgery and Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, 27710, USA.
Priyanka SaminathanDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, 14642, USA.
Ramona M RodriguizDepartment of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine Analysis Core Facility, Duke University Medical Center, Durham, NC, 27710, USA.
William C WetselDepartment of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine Analysis Core Facility, Duke University Medical Center, Durham, NC, 27710, USA.
Harris A GelbardCenter for Neurotherapeutics Discovery, University of Rochester Medical Center, Rochester, NY, 14642, USA. Harris_Gelbard@URMC.Rochester.edu.
Niccolò TerrandoCenter for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA. niccolo.terrando@duke.edu.ORCID http://orcid.org/0000-0003-1803-5853
Duke University · USUniversity of Rochester Medical Center · USDuke Medical Center · US

Funding

Targeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4M
Neurovascular dysfunction in delirium superimposed on dementiaR01AG057525 · NIA · DUKE UNIVERSITY · PI Niccolo Terrando · 2017 to 2026
$6.7M
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1R01MH104147 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2014 to 2018
$3.2M
Regulation of Tissue Macrophage Immune Activation by MafbF31MH113504 · NIMH · UNIVERSITY OF ROCHESTER · PI MILLER-RHODES, PATRICK · 2017 to 2018
$88k
NIA NIH HHS R01 AG057525NIA NIH HHS RO1 AG057525NIMH NIH HHS F31 MH113504NIMH NIH HHS P01MH64570NIMH NIH HHS R01 MH104147NIMH NIH HHS RO1 MH104147
6 · The paper itself

Abstract

backgroundPatients with pre-existing neurodegenerative disease commonly experience fractures that require orthopedic surgery. Perioperative neurocognitive disorders (PND), including delirium and postoperative cognitive dysfunction, are serious complications that can result in increased 1-year mortality when superimposed on dementia. Importantly, there are no disease-modifying therapeutic options for PND. Our lab developed the "broad spectrum" mixed-lineage kinase 3 inhibitor URMC-099 to inhibit pathological innate immune responses that underlie neuroinflammation-associated cognitive dysfunction. Here, we test the hypothesis that URMC-099 can prevent surgery-induced neuroinflammation and cognitive impairment.

methodsOrthopedic surgery was performed by fracturing the tibia of the left hindlimb with intramedullary fixation under general anesthesia and analgesia. In a pilot experiment, 9-month-old mice were treated five times with URMC-099 (10 mg/kg, i.p.), spaced 12 h apart, with three doses prior to surgery and two doses following surgery. In this experiment, microgliosis was evaluated using unbiased stereology and blood-brain barrier (BBB) permeability was assessed using immunoglobulin G (IgG) immunostaining. In follow-up experiments, 3-month-old mice were treated only three times with URMC-099 (10 mg/kg, i.p.), spaced 12 h apart, prior to orthopedic surgery. Two-photon scanning laser microscopy and CLARITY with light-sheet microscopy were used to define surgery-induced changes in microglial dynamics and morphology, respectively. Surgery-induced memory impairment was assessed using the "What-Where-When" and Memory Load Object Discrimination tasks. The acute peripheral immune response to surgery was assessed by cytokine/chemokine profiling and flow cytometry. Finally, long-term fracture healing was assessed in fracture callouses using micro-computerized tomography (microCT) and histomorphometry analyses.

resultsOrthopedic surgery induced BBB disruption and microglial activation, but had no effect on microglial process motility. Surgically treated mice exhibited impaired object place and identity discrimination in the "What-Where-When" and Memory Load Object Discrimination tasks. Both URMC-099 dosing paradigms prevented the neuroinflammatory sequelae that accompanied orthopedic surgery. URMC-099 prophylaxis had no effect on the mobilization of the peripheral innate immune response and fracture healing.

conclusionsThese findings show that prophylactic URMC-099 treatment is sufficient to prevent surgery-induced microgliosis and cognitive impairment without affecting fracture healing. Together, these findings provide compelling evidence for the advancement of URMC-099 as a therapeutic option for PND.

Indexed as

Perioperative CareAnimalsCognitive DysfunctionDisease Models, AnimalFemaleMaleMAP Kinase Kinase KinasesMiceMice, Inbred C57BLMicrogliaMitogen-Activated Protein Kinase Kinase Kinase 11Neurocognitive DisordersPyridinesPyrrolesMAP Kinase Kinase KinasesMitogen-Activated Protein Kinase Kinase Kinase 11PyridinesPyrrolesURMC-099DeliriumIntravital microscopyMicrogliaMixed-lineage kinase 3Postoperative neurocognitive disorders

Identifiers

PMID31660984
PMCPMC6816182
OpenAlexW2981918087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.